CliffBio

Accord Biopharma

Patent cliffs & loss of exclusivity

Company

Official Websitehttps://www.accordbiopharma.com/

2 upcoming patent cliffs

DrugIngredientTypeCliff
  1. CAMCEVI ETMLEUPROLIDE MESYLATESmall mol.Jan 2039
  2. CAMCEVI KITLEUPROLIDE MESYLATESmall mol.Jan 2039
  3. Udenycapegfilgrastim-cbqvBiologic—
  4. Udenycapegfilgrastim-cbqvBiologic—
  5. Udenyca Onbodypegfilgrastim-cbqvBiologic—
  6. Ennumopegfilgrastim-pccgBiologic—
  7. Hercessitrastuzumab-strfBiologic—
  8. Hercessitrastuzumab-strfBiologic—
  9. Imuldosaustekinumab-srlfBiologic—
  10. Imuldosaustekinumab-srlfBiologic—
  11. Imuldosaustekinumab-srlfBiologic—
  12. Osvyrtidenosumab-desuBiologic—
  13. Jubereqdenosumab-desuBiologic—

Loss-of-exclusivity dates are derived from the FDA Orange & Purple Books; company detail is from the CliffBio graph. Estimates are projections, not legal advice.